Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.
Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.
The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.
Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.
One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.
With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.
Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results. Investors can participate by dialing 800-343-4849 (U.S.) or 203-518-9856 (outside U.S.) with the access code: BIORAD. A live webcast will be available on the company's website, and a replay will be accessible for up to a year.
Bio-Rad Laboratories has appointed Anette Engelhardt as Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Engelhardt joins from Cepheid, where she was a Senior Vice President and General Manager. At Cepheid, she managed emerging growth opportunities and led global R&D, strategy, and product management. She has significant experience in the diagnostics field, having held senior roles at bioMerieux and served as CEO of AB BIODISK. Andy Last, Bio-Rad’s Executive VP and COO, expressed confidence in Engelhardt's ability to drive the company's clinical diagnostics strategy and product development.
Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 10:30 AM ET (7:30 AM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website.
Bio-Rad Laboratories, Inc. reported first-quarter 2024 financial results with total net sales of $610.8 million, a decrease of 9.8% compared to the same period in 2023. While Life Science segment sales dropped by 25.3%, Clinical Diagnostics segment sales increased by 4.7%. Net income for the quarter was $383.9 million, or $13.45 per share, compared to $69.0 million, or $2.32 per share, in 2023. Bio-Rad remains cautiously optimistic about a gradual biopharma market recovery and confident in their long-term strategy.
Bio-Rad Laboratories, Inc. will have its COO and CFO participate in a fireside chat during the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be webcasted and available for replay on the company's Investor Relations website.
Bio-Rad Laboratories, Inc. announced the promotion of James J. Barry to Executive Vice President and President of the Life Science Group, succeeding Dr. Simon May. Barry's extensive experience and leadership roles in quality systems and global manufacturing make him well-suited for the position. The CEO expressed confidence in Barry's ability to lead the global life science business, acknowledging May's contributions to the company.
FAQ
What does Bio-Rad Laboratories, Inc. specialize in?
When was Bio-Rad Laboratories founded?
Where is Bio-Rad Laboratories headquartered?
What are the core business segments of Bio-Rad?
What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?
How many employees does Bio-Rad have?
What is Bio-Rad's involvement in the biopharmaceutical industry?
What is Bio-Rad's market reach?
What is the significance of Bio-Rad's ownership in Sartorius?
How does Bio-Rad contribute to scientific research and development?
